NICE methodology for technology appraisals: Cutting edge or tried and trusted?

PharmacoEconomics

Volumn 26, Issue 9, 2008, Pages 729-732

  Longworth, Louise ^a,b   Longson, Carole ^a  

^a NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APPRAISAL COMMITTEE; BIOMEDICAL TECHNOLOGY ASSESSMENT; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DECISION SUPPORT SYSTEM; EDITORIAL; EUROPEAN QUALITY OF LIFE 5 DIMENSION DATA ANALYSIS; GUIDE TO THE METHODS OF TECHNOLOGY APPRAISAL; HEALTH PROGRAM; HUMAN; MEDICAL DECISION MAKING; ORGANIZATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; UNCERTAINTY; UNITED KINGDOM;

ACADEMIES AND INSTITUTES; DECISION MAKING; GREAT BRITAIN; GUIDELINES AS TOPIC; HUMANS; ORGANIZATIONAL OBJECTIVES; POLICY MAKING; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 51149095990     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826090-00003     Document Type: Editorial

References (17)

1. National Institute for Clinical Excellence. Guide to the methods of technology appraisal (ref N01505). London: NICE, 2004 [online]. Available from URL: http://www.nice.org.uk/aboutnice/ howwework/devnicetech/ technologyappraisalprocessguides/ guide_to_the_methods_of_technology_appraisal_reference_n0515.jsp [Accessed 2008 Aug 5]
2. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal (ref N1618). London: NICE, 2008 [online]. Available from URL: http://www.nice.org.uk/media/B52/A7/ TAMethodsGuideUpdatedJune2008. pdf [Accessed 2008 Aug 5]
3. Brazier J. Valuing health states for use in cost-effectiveness analysis. Pharmacoeconomics 2008; 26 (9): 769-79
4. Claxton K. Exploring uncertainty in cost-effectiveness analysis. Pharmacoeconomics 2008; 26 (9): 781-98
5. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 2008; 26 (9): 733-44
6. Miners A. Estimating 'costs' for cost-effectiveness analysis. Pharmacoeconomics 2008; 26 (9): 745-51
7. Sculpher M. Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics 2008; 26 (9): 799-806
8. Sutton A, Ades AE, Cooper N, et al., on behalf of the NICE Decision Support Unit. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 2008; 26 (9): 753-67
9. Martin S, Rice N, Smith PC. Further evidence on the link between health care spending and health outcomes in England [Centre for Health Economics Research Paper 32]. York: University of York, 2007
10. National Institute for Health and Clinical Excellence. Continuous subcutaneous insulin infusion for the treatment of diabetes. NICE technology appraisal guidance 151. London: NICE, 2008 [online]. Available from URL: http://www.nice.org.uk/guidance/TA151 [Accessed 2008 Aug 6]
11. National Institute for Health and Clinical Excellence. Cetux imab for the treatment of head and neck cancer. NICE technology appraisal guidance 145. London: NICE, 2008 [online]. Available from URL: http://www.nice.org.uk/ guidance/TA145 [Accessed 2008 Aug 6]
12. National Institute for Health and Clinical Excellence. Infliximab for the treatment of psoriasis. NICE technology appraisal guidance 134. London: NICE, 2008 [online]. Available from URL: http://www.nice.org.uk/guidance/TA134 [Accessed 2008 Aug 6]
13. National Institute for Health and Clinical Excellence. Omalizumab for severe persistent allergic asthma. NICE technology appraisal guidance 133. London: NICE, 2007 [online]. Available from URL: http://www.nice.org.uk/ guidance/TA133 [Accessed 2008 Aug 6]
14. National Institute for Health and Clinical Excellence. Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis. NICE technology appraisal guidance 127. London: NICE, 2007 [online]. Available from URL: http://www.nice.org.uk/guidance/TA127 [Accessed 2008 Aug 6]
15. National Institute for Health and Clinical Excellence. Carmustine implants and temozolomide for the treatment of newly diagnosed high grade glioma. NICE technology appraisal guidance 121. London: NICE, 2008 [online]. Available from URL: http://www.nice.org.uk/guidance/TA121 [Accessed 2008 Aug 6]
16. National Institute for Health and Clinical Excellence. Cardiac resynchronisation therapy for the treatment of heart failure. NICE technology appraisal guidance 120. London: NICE, 2007 [online]. Available from URL: http://www.nice.org.uk/guidance/TA120 [Accessed 2008 Aug 6]
17. National Institute for Health and Clinical Excellence. Etanercept and efalizumab for the treatment of adults with psoriasis. NICE technology appraisal guidance 103. London: NICE, 2006 [online]. Available from URL: http://www.nice.org.uk/guidance/TA103 [Accessed 2008 Aug 6]